Multiple prospective trials have demonstrated that HR+/HER2+ breast cancer exhibits lower pCR rates compared to HR-/HER2+ breast cancer under current HER2-targeted treatment strategies. This evidence concerns the gene ERBB2 and breast carcinoma.